Year: 2020
Type: article
Abstract: Except one notable drug -Artemisinin (ART), resistance has been developed to all known antimalarial drugs.For centuries, Artemisinins have been used as traditional Chinese herbal medicine, derived from the plant, Artemisia annua and proved its effi cacy against the life-threatening disease [12,13].To prevent the emergence of resistance, artemisinins in combination with partner drugs, where other antimalarial drugs like chloroquine, sulfadioxinepyrimethamine etc. are used as partners, are widely used.Due to the high potency of ART with slow-acting and less potent partner drugs, ACTs are known for higher parasite killing rate, lack of side eff ects and absence of resistance [14][15][16]. ABSTRACTMalaria has remained a life threatening disease in South-East Asia and Sub-Saharan Africa for decades.Many eff orts have been spent on Global and regional surveillance of malaria burden.Over US$ 2.7 billion was invested in malaria control and elimination globally in 2018.Insecticide-treated mosquito nets, rapid diagnostic tests andArtemisinin-based combination therapy are the three major pillars that malaria control and elimination currently relies on.Insecticide resistances as well as the anti-malarial drug resistance have emerged as the major road blocks in winning the war against malaria.Here we discuss in details the artemisinin chemotherapy, the resistance phenotypes associated with its widespread use and the molecular marker associated with artemisinin drug resistance.Specifi cally we discuss the surveillanceof K13 genotypes as an essential step in tracking the ART drug resistance in malaria laden areas.
DOI: 10.37871/sjb.id16
Authors: Sultan Ahmad, Aqeel Ahmad, Alkama Aziz
Language: English
Topic: Malaria Research and Control
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W3035969152